A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2012
This article has no abstract
Epistemonikos ID: 7c914e559ac5c7eda6b060a845bd4e06fb9959ea
First added on: Jan 21, 2025